PJI within 1 Year After TKA Is Linked to Increased Mortality Rate at 10 Years. Reasons Yet to Be Identified

Periprosthetic joint infection (PJI) remains one of the most serious complications after total knee arthroplasty (TKA). It affects not only the knee itself, but also the patient’s general health and quality of life. Ekhtiari et al. deserve credit for a well-performed study. They used the ICES data repository, a large set of linked administrative databases covering almost all health-care events in a single-payer system in Ontario, Canada. Patients who developed PJI within 1 year after primary TKA were matched to those who did not develop PJI during that time. Standardized differences in the assessed covariates indicated adequate matching. Mortality rates were analyzed using Kaplan-Meier curves and compared using log-rank testing. The rate of missing data was very low (<1%). I find this approach reasonable, and it shows that population-level trends can be observed, even if individual patient details are missing. At the same time, some limitations are unavoidable in such studies. PJI is not one simple problem; from my experience, every case is different, and administrative data can never fully capture these differences. Moreover, how PJI is diagnosed changed a lot during the 19-year period of the study. The set of databases relies on coded diagnoses, not direct clinical confirmation, so there could be differences in how doctors recorded infection over time. In my clinical practice, I have seen how variable PJI diagnosis can be. This limitation is common for large database studies, and we need to remember it when interpreting the findings. Another important limitation relates to treatment. How a PJI is treated makes a big difference for the patient, but the data set does not include this information. In practice, patients might have DAIR (debridement, antibiotics, and implant retention), single-stage revision, or 2-stage revision, and outcomes differ greatly1. The authors performed a post-hoc analysis using 48 days as a cutoff, as early infections (≤48 days) are more likely to have been treated with DAIR. This is creative, but timing alone cannot perfectly reflect treatment choice. Some infections after 48 days may still be managed with DAIR, and some early infections may require staged revision, depending on the bacteria, tissue condition, or implant stability. Therefore, we cannot assume that mortality differences reflect treatment effects. The difference in 10-year mortality is notable, but we do not know why it happens2,3. Every PJI case is unique, and reducing the comparison to “PJI versus no PJI” hides important differences. In my experience, some patients do much worse than others for reasons that cannot be seen in databases. In this sense, the study shows a signal, but it does not prove mortality causation, which the authors acknowledge. Even with these limits, the results are very important. They remind us that PJI may have long-term effects beyond the knee joint, so prevention, early recognition, and careful management are also very important. Furthermore, the study also shows the value of large databases in detecting trends that smaller studies might miss, but it also shows their limits in determining mechanisms. In conclusion, this study offers strong evidence that PJI within 1 year after TKA is associated with higher risk of 10-year mortality, a finding that aligns with recent similar studies of total knee and total hip arthroplasty1–5. The study is well done and has statistical strength. At the same time, the absence of treatment details, changes in diagnostic criteria, and unknown mechanisms require cautious interpretation. From my point of view as a surgeon, these results make me more attentive to prevention and early management but also remind me that we cannot fully understand individual outcomes from database trends alone. These limits do not reduce the value of the work. Instead, they show that we need prospective studies and registries with more clinical, microbiologic, and treatment information. Only with such data can we understand why mortality is higher and how to improve outcomes for this very challenging complication.